Recursion Pharmaceuticals (RXRX) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Recursion Pharmaceuticals (NASDAQ: RXRX) in the last few weeks:

• 10/19/2026 – Recursion Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
• 10/17/2026 – Recursion Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/16/2026 – Recursion Pharmaceuticals was given a new $5.90 price target by Morgan Stanley.
• 10/15/2026 – Recursion Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Recursion Pharmaceuticals Trading Down 3.9%

Shares of Recursion Pharmaceuticals stock traded down $0.15 on Tuesday, hitting $3.68. The stock had a trading volume of 20,664,956 shares, compared to its average volume of 19,658,025. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $5.32. The stock’s 50-day simple moving average is $3.75 and its two-hundred day simple moving average is $3.54. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -3.54 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. The firm had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. During the same period in the previous year, the firm earned ($0.36) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.93 EPS for the current year.

Insider Activity

In related news, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the completion of the transaction, the director directly owned 162,156 shares of the company’s stock, valued at $810,780. This trade represents a 13.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the transaction, the director owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. The trade was a 0.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 127,408 shares of company stock worth $546,076. Corporate insiders own 6.65% of the company’s stock.

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.